Skip to main navigation Skip to search Skip to main content

Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia

  • Enrique Teran*
  • , Carlos Escudero
  • , Sandra Vivero
  • , Armando Enriquez
  • , Andres Calle
  • *Corresponding author for this work
  • Universidad Central del Ecuador
  • Hospital Gineco Obstetrico Isidro Ayora

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Objective: To investigate the intraplatelet cyclic guanosine-3′, 5′-monophosphate (cGMP) levels during normal pregnancy and preeclampsia. Study Design: Pregnant women (n = 15), women with preeclampsia (n = 15), and nonpregnant, normotensive women (n = 15) were included. Intraplatelet cyclic guanosine-3′,5′-monophosphate levels were measured by an enzyme-linked immunosorbent assay. Results: Intraplatelet cGMP levels were significantly different among all groups (p < 0.02). The values were higher in normal pregnant women (mean 19.8 SD 2.6 fmol/105 platelets) in comparison to nonpregnant women (mean 7.6 SD 0.3 fmol/105 platelets; p = 0.001) and women with preeclampsia (mean 11.3 SD 1.8 fmol/105 platelets; p = 0.05). Plasma nitric oxide levels did not reveal differences between all groups. Conclusions: The results of this study in a high-risk Andean population demonstrated that intraplatelet cyclic guanosine-3′,5′- monophosphate levels are decreased during preeclampsia compared to normal pregnancy, suggesting a lack in action of nitric oxide.

Original languageEnglish
Pages (from-to)303-308
Number of pages6
JournalHypertension in Pregnancy
Volume23
Issue number3
DOIs
StatePublished - 2004
Externally publishedYes

Keywords

  • Nitric oxide
  • Platelets
  • Preeclampsia
  • Pregnancy
  • cGMP

Fingerprint

Dive into the research topics of 'Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia'. Together they form a unique fingerprint.

Cite this